Hugo Vanderstichele

Overview

Best Publications

• Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

  Leslie M. Shaw;Hugo Vanderstichele;Malgorzata Knapik-Czajka;Christopher M. Clark

  2374
  Citations

• Improved discrimination of AD patients using beta-amyloid((1-42)) and tau levels in CSF

  F Hulstaert;K Blennow;A Ivanoiu;HC Schoonderwaldt

  955
  Citations

• Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

  Niels Andreasen;Camilla Hesse;Pia Davidsson;Lennart Minthon

  811
  Citations

• Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

  Niels Andreasen;Lennart Minthon;Pia Davidsson;Eugeen Vanmechelen

  774
  Citations

• Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency

  An Herreman;Dieter Hartmann;Wim Annaert;Paul Saftig

  753
  Citations

• Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.

  Harald Hampel;Katharina Buerger;Raymond Zinkowski;Stefan J. Teipel

  592
  Citations

• Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.

  E Vanmechelen;H Vanderstichele;P Davidsson;E Van Kerschaver

  584
  Citations

• Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

  Camilla Hesse;Lars Rosengren;Niels Andreasen;Pia Davidsson

  549
  Citations

• Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People

  Geert De Meyer;Fred Shapiro;Hugo Vanderstichele;Eugeen Vanmechelen

  541
  Citations

• Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values.

  Magnus Sjögren;Hugo Vanderstichele;Hans Ågren;Olof Zachrisson

  533
  Citations

• Simultaneous Measurement of β-Amyloid(1–42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology

  Annika Olsson;Hugo Vanderstichele;Niels Andreasen;Geert De Meyer

  522
  Citations

• CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

  Shorena Janelidze;Henrik Zetterberg;Niklas Mattsson;Sebastian Palmqvist

  483
  Citations

• Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.

  Hugo Vanderstichele;Mirko Bibl;Sebastiaan Engelborghs;Nathalie Le Bastard

  468
  Citations

• The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

  Niklas Mattsson;Ulf Andreasson;Staffan Persson;Hiroyuki Arai

  452
  Citations

• Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease.

  Pratishtha Chatterjee;Pratishtha Chatterjee;Steve Pedrini;Erik Stoops;Kathryn Goozee

  436
  Citations

• Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

  Leslie M. Shaw;Hugo Vanderstichele;Malgorzata Knapik-Czajka;Michal Figurski

  428
  Citations

• Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.

  H Vanderstichele;E Van Kerschaver;C Hesse;P Davidsson

  395
  Citations

• Evaluation of plasma A beta(40) and A beta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

  Oskar Hansson;Oskar Hansson;Henrik Zetterberg;Eugeen Vanmechelen;Hugo Vanderstichele

  362
  Citations

• Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment

  N Andreasen;Lennart Minthon;E Vanmechelen;H Vanderstichele

  326
  Citations

• Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.

  Sebastiaan Engelborghs;Karen De Vreese;Tom Van de Casteele;Hugo Vanderstichele

  324
  Citations

• Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

  H. Vanderstichele;M. Bibl;S. Engelborghs;N. Le Bastard

  0
  Citations